Have any questions? 706-721-6582 or cts@augusta.edu
- AVA-CIT-330: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancer
Clinical Trial
AVA-CIT-330: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancer
Avatrombopag is an investigational medicine being tested for the prevention of low platelets, and is not commercially available. During this study, staff will follow each participant's need for platelet transfusions and chemotherapy delays or dose reductions to control low platelets, to find out if patients who take the study drug need fewer transfusions and delays than patients who do not take the study drug. In addition, they will follow each patient's health to find out more about the safety of avatrombopag. The study will also test how the study drug is processed by the body, such as how quickly the study drug gets into the blood, how the study drug is broken down by the body.
- Female Reproductive System
- Respiratory System
- Urinary System
- Bladder Cancer
- Cancer
- Non-small Cell Lung Cancer
- Oncology
- Ovarian
Eligibility Criteria
- Eligible subjects must be at least 18 years of age or older Must be diagnosed with ovarian cancer, non-small cell lung cancer, or bladder cancer, requiring systemic chemotherapy Subjects with a platelet count grater than 175 x 1069/L at Visit 2 (-1 day) will not be eligible.